Pharmaceuticals

A first-in-class drug, NTX-2001, is now in human trials for alcohol use disorder, offering a new mechanism of action in a field with few options.

With a fourfold revenue jump, China's Yangtze River Pharmaceutical Group isn't just selling drugs; it's exporting a new model of global trust and quality.

Henlius and Organon's POHERDY gains EC approval, set to expand access and lower costs for a critical breast cancer therapy across the European Union.

A novel topical gel that boosts cellular energy is now in late-stage trials, offering new hope for healing the chronic wounds of diabetic foot ulcers.

Genomics' big data and Greywolf's novel drugs unite to develop first-in-class treatments for autoimmune diseases, promising a new era of precision medicine.

A landmark deal sees a major pharma manufacturer adopt Kneat Gx, signaling a pivotal shift towards digital automation and data integrity in life sciences.

YPrime's new AI Calculation Engine lets researchers use plain language to build complex trial logic, aiming to slash setup times and boost data accuracy.

The pharma giant reports a net loss after a major write-down, but management points to a strong consumer division and a CDMO rebound as signs of recovery.

A new partnership brings sustainable, wash-free lab tech to the GCC & MENA, aiming to accelerate drug discovery in the world's fastest-growing life-science market.

A Dubai hospital pioneers a one-time gene therapy for an adult with SMA, offering new hope to a patient population previously left with limited options.

A new ultra-short-acting drug for cardiac emergencies is now in US hospitals, offering doctors faster control and broader use across all age groups.

A new FDA-Paradigm Health partnership uses AI to review clinical trial data in real time, aiming to cut drug development costs and approval delays.

Vensica Medical gets FDA clearance for a Phase 2 study of its ultrasound device that delivers botulinum toxin without needles for overactive bladder.

A new HHS agenda reopens the door for controversial peptides, just as a wave of next-gen obesity drugs threatens to upend the entire market.

Kiniksa raises its 2026 ARCALYST forecast after a blowout quarter, using its financial strength to advance a pipeline aimed at redefining pericarditis care.

With a massive Series A, Coultreon Biopharma is advancing a novel SIK3 inhibitor spun out of Galapagos to rival injectable blockbusters for autoimmune disease.

BRC Therapeutics gets the FDA green light for BRC-002, a novel cannabinoid drug for CRPS, a severe pain condition with no approved US treatments.

Pharma manufacturer Mikart cuts the ribbon on a new Atlanta HQ while boosting bottling capacity by 50%, tackling industry demand and fueling local growth.

A new partnership between insurer Chubb and tech firm VCT introduces a proactive approach to prevent trial risks, enhancing patient safety and data integrity.

A new collaboration aims to merge drugs with AI-driven apps, creating a novel class of therapy that could revolutionize treatment, starting with rare cancers.